Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 1.00 |
| ▸ | MMP2 | P08253 | 6/20 | 0.80 |
| ▸ | MMP1 | P03956 | 6/20 | 0.80 |
| ▸ | MMP3 | P08254 | 3/20 | 0.80 |
| ▸ | MMP9 | P14780 | 3/20 | 0.80 |
| ▸ | CTSD | P07339 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693892 | 0.89 | MMP13 (1.00) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6690704 | 0.84 | MMP13 (0.72) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6694968 | 0.81 | MMP13 (1.00) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL7673136 | 0.81 | MMP13 (0.80) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6693840 | 0.79 | MMP13 (0.81) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6688862 | 0.79 | MMP13 (1.00) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6693895 | 0.78 | MMP13 (0.78) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6691597 | 0.77 | MMP13 (0.77) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL7672124 | 0.77 | MMP13 (0.77) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL6693853 | 0.77 | MMP13 (1.00) | MMP13MMP2MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | claimed |
| US-6458822-B2 | (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES | PFIZER INC. | 2002-10-01 | — | — | US | claimed |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | PFIZER PRODUCTS INC. | 2001-11-15 | — | — | US | claimed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1377586-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | disclosed |
| US-6458822-B2 | (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES | PFIZER INC. | 2002-10-01 | — | — | US | disclosed |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | PFIZER PRODUCTS INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | MMP13 3/4885MMP2 9/4885MMP1 1/4885 |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | MMP13 3/4885MMP2 9/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.